Chardan Capital Reiterates “Buy” Rating for SAB Biotherapeutics (NASDAQ:SABS)
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a report issued on Thursday,Benzinga reports. They presently have a $25.00 price objective on the stock. SABS has been the topic of several other reports. HC Wainwright reissued a “buy” rating and issued a $6.00 […]
More Stories
US Allows Venezuela to Fund Maduro’s Defense After Court Challenge
By Tom Gantert The United States will ease sanctions on Venezuela to allow its regime to pay legal fees for...
Monsanto Weedkiller Case Could Upend Billions in Compensation
By Troy Myers and Jacob Burg Like countless homeowners, John Durnell of Missouri used a popular herbicide to keep his...
Planned Obsolescence: The Silent Sabotage of the Devices We Depend On
By Stephen Zogopoulos, USNN World News The Illusion of Progress Walk into any electronics store today and you’ll see the...
Shots Fired at White House Correspondents’ Dinner, Trump Evacuated, Suspect Detained
By Emel Akan and Sam Dorman President Donald Trump and First Lady Melania Trump were evacuated from the White House...
US Forces Intercept, Turn Back Iran-Linked Tanker in Arabian Sea
By Ryan Morgan A U.S. Navy helicopter intercepted and turned back toward Iran a sanctioned petrochemical tanker in the Arabian...
Iran Offered Better Deal ‘10 Minutes’ After US Canceled Pakistan Meeting, Trump Says
By Jacki Thrapp The Iranian regime offered the United States a “much better” peace deal within 10 minutes of President...